Long-term prognosis of breast cancer detected by mammography screening or other methods

Breast Cancer Research

Johan Lundin⁸  Heikki Joensuu⁷  Jorma Isola⁶  Vesa Kataja¹  Taina Turpeenniemi-Hujanen²  Kaija Holli⁵  Harri Sihto⁴  Nina Linder³  Mikael Lundin³  Tiina Lehtimäki³ 

[1] Cancer Center, Kuopio University Central Hospital, Puijonlaaksontie 2, PO Box 1777, FI-70211, Kuopio, Finland;Department of Oncology and Hematology, Oulu University Central Hospital, Kajaanintie 50, PO Box 20, FI-90029, Oulu, Finland;Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Biomedicum Helsinki 2U, Tukholmankatu 8, PO Box 20, FI-00014 Helsinki, Finland;Molecular Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Tukholmankatu 8, PO Box 20, FI-00014, Helsinki, Finland;Departments of Palliative Medicine and Oncology, Tampere University Hospital and University of Tampere, Teiskontie 35, PO Box 2000, FI-33521,Tampere, Finland;Institute of Medical Technology, University of Tampere and Tampere University Hospital, Biokatu 8-12, PO Box 2000, FI-33520,Tampere, Finland;Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FI-00029, Helsinki, Finland;Division of Global Health, Karolinska Institutet, SE-17177, Stockholm, Sweden

关键词: survival analysis;    prognosis;    mammography;    screening;   

Others  :  799081
DOI  :  10.1186/bcr3080

 received in 2011-07-01, accepted in 2011-12-28,  发布年份 2011

【 摘 要 】

Introduction

Previous studies of breast cancer have shown that patients whose tumors are detected by mammography screening have a more favorable survival. Little is known, however, about the long-term prognostic impact of screen detection. The purpose of the current study was to compare breast cancer-specific long-term survival of patients whose tumors were detected in mammography screening compared with those whose tumors were detected by other methods.

Methods

Breast cancer patients diagnosed within five specified geographical areas in Finland in 1991 and 1992 were identified (N = 2,936). Detailed clinical, treatment and outcome data, as well as tissue samples, were collected. Women with in situ carcinoma, distant metastases at the time of primary diagnosis and women who were not treated surgically were excluded. The main analyses were performed after excluding patients with other malignancy or contralateral breast cancer, followed by sensitivity analyses with different exclusion criteria. Median follow-up time was 15.4 years. Univariate and multivariate analyses of breast cancer-specific survival were performed.

Results

Of patients included in the main analyses (n = 1,884), 22% (n = 408) of cancers were screen-detected and 78% (n = 1,476) were detected by other methods. Breast cancer-specific 15-year survival was 86% for patients with screen-detected cancer and 66% for patients diagnosed using other methods (P < 0.0001, HR = 2.91). Similar differences in survival were observed in women at screening age (50 to 69 years), as well as in clinically important subgroups, such as patients with small tumors (≤ 1 cm in diameter) and without nodal involvement (N0). Women with breast cancer diagnosed on the basis of screening mammography had a more favorable prognosis than those diagnosed outside screening programs, following adjustments according to patient age, tumor size, axillary lymph node status, histological grade and hormone receptor status. Significant differences in the risk of having future contralateral breast cancer according to method of detection were not observed.

Conclusions

Breast cancer detected by mammography screening is an independent prognostic factor in breast cancer and is associated with a more favorable survival rate as well as in long-term follow-up.

【 授权许可】

   
2012 Lehtimäki et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999, 91:2020-2028.
• [2]Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC: Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009, 101:1338-1344.
• [3]Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203.
• [4]Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ, Elston CW, Ellis IO, Blamey RW, Robertson JF: Screening interval breast cancers: mammographic features and prognosis factors. Radiology 1996, 199:811-817.
• [5]Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT: The new era in breast cancer: invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996, 131:301-308.
• [6]Pálka I, Kelemen G, Ormándi K, Lázár G, Nyári T, Thurzó L, Kahán Z: Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 2008, 14:161-167.
• [7]Cady B: New era in breast cancer: impact of screening on disease presentation. Surg Oncol Clin N Am 1997, 6:195-202.
• [8]Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, Bianchi S, Cataliotti L, del Turco MR: Are breast cancer screening programmes increasing rates of mastectomy? Observational study. BMJ 2002, 325:418.
• [9]Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H: Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008, 14:4103-4110.
• [10]Crosier M, Scott D, Wilson RG, Griffiths CDM, May FEB, Westley BR: Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 1999, 5:2682-2688.
• [11]Groenendijk RP, Bult P, Tewarie L, Peer PG, van der Sluis RF, Ruers TJ, Wobbes T: Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer 2000, 82:381-384.
• [12]Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y: Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 2008, 17:1096-1103.
• [13]Ernst MF, Roukema JA, Coebergh JW, Repelaer van Driel OJ, van Beek MW, van der Sangen MJ, Voogd AC: Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Res Treat 2002, 76:19-25.
• [14]Gabriel H, Wilson TE, Helvie MA: Breast cancer in women 65-74 years old: earlier detection by mammographic screening. AJR Am J Roentgenol 1997, 168:23-27.
• [15]Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M: Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. Anticancer Res 2003, 23:4213-4218.
• [16]Klemi PJ, Toikkanen S, Räsänen O, Parvinen I, Joensuu H: Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 1997, 75:762-766.
• [17]Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292:1064-1073.
• [18]Mook S, Van 't Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK: Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 2011, 103:585-597.
• [19]Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 2008, 98:1741-1744.
• [20]Immonen-Räihä P, Kauhava L, Parvinen I, Holli K, Kronqvist P, Pylkkänen L, Helenius H, Kaljonen A, Räsänen O, Klemi PJ: Mammographic screening reduces risk of breast carcinoma recurrence. Cancer 2005, 103:474-482.
• [21]Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, Wallis M, Lawrence G: Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 2011, 117:1360-1368.
• [22]Jatoi I, Anderson WF, Jeong JH, Redmond CK: Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 2011, 29:2301-2304. A published erratum appears in J Clin Oncol 2011, 29:3948
• [23]Brenner H, Hakulinen T: Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 2004, 22:432-438.
• [24]Joensuu H, Pylkkänen L, Toikkanen S: Late mortality from pT1N0M0 breast carcinoma. Cancer 1999, 85:2183-2189.
• [25]Joensuu H, Toikkanen S: Cured of breast cancer? J Clin Oncol 1995, 13:62-69.
• [26]Warwick J, Tabár L, Vitak B, Duffy SW: Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer 2004, 100:1331-1336.
• [27]Anderson WF, Chen BE, Jatoi I, Rosenberg PS: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 2006, 100:121-126.
• [28]Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, Chiu SY, Chen SL, Fann JC, Rosell J, Fohlin H, Smith RA, Duffy SW: Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011, 260:658-663.
• [29]Tabár L, Duffy SW, Vitak B, Chen HH, Prevost TC: The natural history of breast carcinoma: what have we learned from screening? Cancer 1999, 86:449-462.
• [30]Woloshin S, Schwartz LM: The benefits and harms of mammography screening: understanding the trade-offs. JAMA 2010, 303:164-165.
• [31]Murphy AM: Mammography screening for breast cancer: a view from 2 worlds. JAMA 2010, 303:166-167.
• [32]Kopans DB, Monsees B, Feig SA: Screening for cancer: when is it valid? Lessons from the mammography experience. Radiology 2003, 229:319-327.
• [33]Zahl PH, Strand BH, Maehlen J: Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004, 328:921-924.
• [34]de Koning HJ: Why improvement in survival of screen-detected cases is not necessarily equivalent to benefit? Breast 2003, 12:299-301.
• [35]Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, Allgood PC, Kearins O, Tappenden N, O'Sullivan E, Lawrence G: Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008, 168:98-104.
• [36]Berg WA: Benefits of screening mammography. JAMA 2010, 303:168-169.
• [37]Olivotto IA, Mates D, Kan L, Fung J, Samant R, Burhenne LJ: Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia. Breast Cancer Res Treat 1999, 54:73-81.
• [38]Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
• [39]World Health Organization: The World Health Organization Histological Typing of Breast Tumors-Second Edition. Am J Clin Pathol 1982, 78:806-816.
• [40]Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923-930.
• [41]Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000, 157:1467-1472.
• [42]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. A published erratum appears in J Clin Oncol 2010, 28:3543
• [43]Rubino C, Arriagada R, Delaloge S, Lê MG: Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 2010, 102:213-219.
• [44]Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:855-861.
• [45]Horn PL, Thompson WD: Risk of contralateral breast cancer: associations with histologic, clinical, and therapeutic factors. Cancer 1988, 62:412-424.
• [46]Schairer C, Brown LM, Mai PL: Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res Treat 2011, 129:117-124.
• [47]Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK: Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 2009, 115:962-971.
• [48]Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS: Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 1997, 225:69-75.
• [49]Sarkeala T, Heinävaara S, Anttila A: Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer 2008, 122:614-619.
• [50]Li CI, Anderson BO, Daling JR, Moe RE: Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003, 289:1421-1424.
• [51]Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF: Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992, 84:781-785.
• [52]Lopez JK, Bassett LW: Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. Radiographics 2009, 29:165-176.